脑利钠肽不同停药方法对急性前壁心肌梗死合并心力衰竭患者临床疗效观察  

The Clinical Efficacy of Different Methods of Stopping Brain Natriuretic Peptide in Patients with Acute Anterior Myocardial Infarction Complicated with Heart Failure

作　　者：任岩春[1] 赵永峰[1] 张晓蕾[1] 王硕 董静杰 杨艳[1] 张莹洁 REN Yan-chun;ZHAO Yong-feng;ZHANG Xiao-lei;WANG Shuo;DONG Jing-jie;ZHANG Yingjie(Department of Cardiology,First Hospital of Shijiazhuang,Shijiazhuang 050011,China)

机构地区：[1]石家庄市第一医院心内科

出　　处：《标记免疫分析与临床》2019年第8期1343-1345,共3页Labeled Immunoassays and Clinical Medicine

基　　金：石家庄市科学技术研究发展指导计划(编号:161462493)

摘　　要：目的观察脑利钠肽(brain natriuretic peptide,NT- proBNP)逐渐减量停药与突然停药对急性前壁心肌梗死合并心力衰竭临床疗效是否存在差异。方法入选我院2017年1月至2017年12月收治的急性前壁心肌梗死合并心力衰竭患者38例,均予以脑利钠肽泵入,随机分为逐渐减量停药组20例及突然停药对照组18例,测定NT- ProBNP水平,行心脏彩超检查测定左室射血分数,并观察停药后患者心力衰竭控制情况。结果两组患者NT- ProBNP水平及左心室射血分数均有所改善,但逐渐减量停药组患者心力衰竭控制情况优于对照组,且两组之间差异具有统计学意义( P <0.05)。结论急性前壁心肌梗死合并心力衰竭患者在应用脑利钠肽改善心功能、减低心脏负荷治疗时可考虑逐渐减量停药以避免心衰反复而尽量避免突然停药。Objective To observe the potential different clinical efficacies of acute anterior myocardial infarction complicated by heart failure with gradual withdrawal of brain natriuretic peptide versus acute withdrawal. Methods 38 patients enrolled in our hospital from January,2017 to December,2017 with acute anterior myocardial infarction complicated by heart failure were randomly divided into two groups:the progressive reduction group (n=20)and the control group(n=18).Clinical symptoms were observed and NT- ProBNP and LVEF were meaured. Results NT- ProBNP and left ventricular ejection fraction were improved in both groups,but the progressive reduction group was better than the control group in the control of heart failure symptoms( P <0.05). Conclusion Patients with acute anterior myocardial infarction complicated with heart failure should have a gradual reduction of the dose of brain natriuretic peptide.

关 键 词：脑利钠肽 急性前壁心肌梗死 心力衰竭 NT- PROBNP 左室射血分数 

分 类 号：R541.6[医药卫生—心血管疾病] R542.22[医药卫生—内科学]